Abstract: Brain hyper-networks as a kind of hypergraph for brain network analysis, describing the high-order interactions among brain regions, have been extensively utilized in research on brain ...

The Oxford-Harrington Rare Disease Centre ('OHC') today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Disclaimer: The content presented here is for entertainment purposes only and does not guarantee the authenticity or accuracy of the information. The content may contain elements of fiction, ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

Ruth Wilson doesn’t look sick yet “everywhere hurts all the time” – because her immune system is attacking her own body. The Massachusetts woman has lupus, nicknamed the disease of 1,000 faces for its ...

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...

Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19 ...